MedPath

Cipla Ltd.

Cipla Ltd. logo
🇮🇳India
Ownership
Public
Established
1935-01-01
Employees
40.9K
Market Cap
-
Website
http://www.cipla.com

Clinical Trials

184

Active:11
Completed:129

Trial Phases

5 Phases

Phase 1:2
Phase 2:2
Phase 3:30
+2 more phases

Drug Approvals

22

NMPA:10
PHILIPPINES:5
FDA:4
+2 more agencies

Drug Approvals

Levothyroxine Sodium Tablets

Product Name
左甲状腺素钠片
Approval Number
国药准字HJ20240128
Approval Date
Nov 5, 2024
NMPA

Levothyroxine Sodium Tablets

Product Name
左甲状腺素钠片
Approval Number
国药准字HJ20240127
Approval Date
Nov 5, 2024
NMPA

Esomeprazole Magnesium for Delayed-Release Oral Suspension

Product Name
艾司奥美拉唑镁肠溶干混悬剂
Approval Number
国药准字HJ20233132
Approval Date
Feb 28, 2023
NMPA

Esomeprazole Magnesium for Delayed-Release Oral Suspension

Product Name
艾司奥美拉唑镁肠溶干混悬剂
Approval Number
国药准字HJ20233133
Approval Date
Feb 28, 2023
NMPA

Esomeprazole Magnesium for Delayed-Release Oral Suspension

Product Name
艾司奥美拉唑镁肠溶干混悬剂
Approval Number
国药准字HJ20233134
Approval Date
Feb 28, 2023
NMPA

Lamivudine Tablets

Product Name
拉米夫定片
Approval Number
国药准字J20171030
Approval Date
Jan 11, 2019
NMPA

Lamivudine Tablets

Product Name
拉米夫定片
Approval Number
J20171030
Approval Date
Jan 11, 2019
NMPA

Lamivudine tablets

Product Name
拉米夫定片
Approval Number
H20160653
Approval Date
Dec 22, 2016
NMPA

Lamivudine tablets

Product Name
拉米夫定片
Approval Number
H20160654
Approval Date
Dec 22, 2016
NMPA

Lamivudine tablets

Product Name
拉米夫定片
Approval Number
H20160655
Approval Date
Dec 22, 2016
NMPA

Clinical Trials

Distribution across different clinical trial phases (156 trials with phase data)• Click on a phase to view related trials

Phase 4
81 (51.9%)
Not Applicable
41 (26.3%)
Phase 3
30 (19.2%)
Phase 1
2 (1.3%)
Phase 2
2 (1.3%)

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

First Posted Date
2023-12-04
Last Posted Date
2025-07-16
Lead Sponsor
Cipla Ltd.
Target Recruit Count
120
Registration Number
NCT06154304
Locations
🇺🇸

Velocity CLinical Research, Medford, Oregon, United States

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol
Drug: Placebo
First Posted Date
2022-04-12
Last Posted Date
2023-08-30
Lead Sponsor
Cipla Ltd.
Target Recruit Count
1485
Registration Number
NCT05322707
Locations
🇺🇸

Velocity Clinical Research, Medford, Oregon, United States

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

First Posted Date
2018-01-09
Last Posted Date
2020-08-13
Lead Sponsor
Cipla Ltd.
Target Recruit Count
1366
Registration Number
NCT03394989
Locations
🇺🇸

Combined Research Orlando, Orlando, Florida, United States

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

Phase 3
Completed
Conditions
Bronchial Asthma
Interventions
Drug: Placebo
Drug: 180 mcg Reference Product
Drug: 90 mcg Reference Product
Drug: 90 mcg Test Product
First Posted Date
2015-12-08
Last Posted Date
2019-07-25
Lead Sponsor
Cipla Ltd.
Target Recruit Count
110
Registration Number
NCT02624505
Locations
🇺🇸

Colorado Allergy and Asthma Centers, Denver, Colorado, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.